<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal CancerChristos S. Karapetis, John Zalcberg, Shirin Khambata‐Ford et al.|New England Journal of Medicine|2008Cited by 3.6k
Cetuximab for the Treatment of Colorectal CancerDerek J. Jonker, Malcolm J. Moore, Chris J. O’Callaghan et al.|New England Journal of Medicine|2007Cited by 1.8k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trialKohei Shitara, Einat Shacham‐Shmueli, Xinqun Chen et al.|The Lancet|2018Cited by 1.3k
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Salvatore Siena et al.|The Lancet Oncology|2019Cited by 537
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17Stephanie Yasmin Brule, Rachel Goodwin, Derek J. Jonker et al.|European Journal of Cancer|2015Cited by 337